Saturday 17 October 2026
Export SBFM’s income statement to Excel — free account
Sunshine Biopharma, Inc.
SBFM Healthcare Drug Manufacturers Specialty & Generic
Sunshine Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.3 million, up 4.11% from fiscal 2024. In the quarter to June 2026, revenue fell 1.56%, EPS grew 70.5% and free cash flow grew 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
0.22
0.01
−4.35%
Follow SBFM
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 5 | 4 | 4 | 2 | 4 |
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | (266.61) | (26.97) | (16.11) | (4.10) | (1.43) | (1.70) | (1.72) |
P/S ratio |
— | — | — | 853.08 | 87.96 | 102.32 | 2.74 | 0.30 | 0.06 | 0.14 |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | (675.60) | (67.41) | (49.39) | (5.27) | (0.53) | (0.93) | (1.63) |
P/Operating CF |
— | — | — | (140.85) | (14.82) | (74.91) | (5.31) | (2.65) | (0.62) | (3.16) |
Beneish M-Score |
— | — | — | — | (9.29) | (22.88) | 21.55 | 2.31 | (0.54) | (2.96) |
P/B ratio |
— | — | — | 0.00 | 0.00 | 209.31 | 0.55 | 0.34 | 0.09 | 0.22 |
Price to Tangible BV |
— | — | — | 0.00 | 0.00 | 0.00 | 0.57 | 0.36 | 0.10 | 0.24 |
EV/Sales |
— | — | — | 867.10 | 87.38 | 101.68 | (1.84) | (0.30) | (0.16) | (0.06) |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | 0.00 | 0.93 | 1.57 | 1.02 | 0.51 |
EV/Operating CF |
— | — | — | (36.90) | (9.49) | (12.70) | 1.53 | 0.83 | 0.45 | 0.40 |
EV/FCF |
— | — | — | (37.06) | (9.45) | (12.68) | 1.47 | 0.76 | 0.39 | 0.34 |
Quick Ratio |
0.21 | 0.14 | 0.12 | 0.05 | 0.94 | 22.51 | 3.43 | 3.39 | 2.15 | 1.95 |
Current Ratio |
0.21 | 0.16 | 1.21 | 0.08 | 0.98 | 24.08 | 3.94 | 4.48 | 4.11 | 4.17 |
Net Debt/EBITDA |
0.15 | 0.03 | (0.16) | 0.06 | 0.07 | 0.06 | 2.52 | 3.51 | 1.73 | 2.20 |
Debt/Assets |
0.00% | 30.95% | 25.27% | 0.00% | 90.77% | 86.25% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | (0.14) | (5.19) | 0.00 | (0.99) | 8.98 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.03 | 0.12 | 0.14 | 0.28 | 0.85 | 1.20 | 1.20 |
Operating CF/Net income |
0.09 | 0.52 | 0.24 | 0.30 | 0.24 | 0.15 | 0.20 | 1.95 | 2.44 | 0.89 |
Capex/Depreciation |
(0.01) | (0.56) | (0.38) | (0.07) | (0.09) | 0.00 | (0.02) | (5.29) | (8.86) | (0.40) |
Interest Coverage |
(28.62) | (8.18) | (8.11) | (5.54) | (3.43) | (7.42) | (685.30) | (34.85) | (660.47) | — |
| 771.30% | 235.58% | 591.39% | 372.60% | 302.59% | 2,637.37% | (246.06%) | (21.04%) | (22.97%) | (25.69%) | |
| (948.00%) | (646.29%) | (307.13%) | (266.78%) | (486.90%) | (765.70%) | (170.09%) | (15.92%) | (17.73%) | (19.71%) | |
ROIC |
0.00% | 0.00% | (589.22%) | 0.00% | 0.00% | (2,293.33%) | 0.00% | (60.85%) | (26.30%) | (27.97%) |
Return on Tangible Assets |
1,667.48% | 181.25% | (921.45%) | 225.80% | 47,188.14% | (588.93%) | (128.73%) | (22.87%) | (25.42%) | (28.50%) |
Average Days of Receivables |
— | — | — | 6.92 | 9.71 | 12.47 | 160.61 | 38.67 | 40.49 | 34.78 |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | 72.04% | 2.38% | 294.31% | 18.68% | 7.70% | 2.68% | 1.66% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 2,951.18% | 849.58% | 816.90% | 219.39% | 46.15% | 43.94% | 48.33% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.05 | 0.10 | 0.06 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 1,240.28% | 70.03% | 401.93% | 0.00% | 0.00% | 0.03% | 0.00% |
Graham Net Nets |
— | — | — | (0.04) | (0.16) | 0.01 | 1.65 | 2.63 | 8.98 | 3.87 |
Graham Number |
— | — | — | 10,360.79 | 113,823.76 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | (8.44%) | (86.93%) | (40.73%) | (246.98%) | (69.58%) | (243.70%) | (120.33%) |
Free Cash Flow Yield |
— | — | — | (2.74%) | (10.51%) | (7.83%) | (45.68%) | (134.24%) | (688.71%) | (120.62%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 42.20 | 714.00 | 2,284.00 | 5,432.00 | 18,532.92 | 496.78 | 87.34 |
Operating CF per Share |
(14.82) | (247.05) | (2,564.00) | (991.60) | (6,573.00) | (18,291.00) | (6,560.50) | (6,750.08) | (178.42) | (12.82) |
Capex per Share |
(0.16) | (1.68) | (94.50) | (1.80) | (12.00) | 0.00 | (381.25) | (606.23) | (28.20) | (2.01) |
Free Cash Flow per Share |
(14.98) | (248.73) | (2,658.50) | (993.40) | (6,585.00) | (18,291.00) | (6,941.75) | (7,356.31) | (206.61) | (14.84) |
Cash per Share |
2.71 | 48.86 | 552.50 | 81.00 | 9,899.00 | 20,452.00 | 27,283.00 | 12,532.62 | 137.98 | 21.95 |
Shareholders Equity per Share |
(9.89) | (260.64) | (279.00) | (1,470.80) | (9,548.00) | 2,117.00 | 27,034.50 | 16,313.38 | 334.77 | 55.42 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(9.89) | (260.64) | (279.00) | (1,470.80) | (9,548.00) | 2,117.00 | 27,034.50 | 16,313.38 | 334.77 | 55.42 |
Free Cash Flow |
(0.32) | (0.55) | (0.53) | (0.50) | (0.66) | (1.83) | (5.55) | (9.56) | (14.50) | (6.17) |
Working Capital |
(0.22) | (0.63) | 0.19 | (0.77) | (0.03) | 2.10 | 20.38 | 19.34 | 19.65 | 20.41 |
Capital Expenditures |
0.00 | 0.00 | (0.02) | 0.00 | 0.00 | — | (0.30) | (0.79) | (1.98) | (0.84) |
Net Current Asset Value |
(0.22) | (0.71) | (0.10) | (0.77) | (0.97) | 0.20 | 19.70 | 18.75 | 18.91 | 19.81 |
EV/EBIT |
— | — | — | 0.00 | 0.00 | 0.00 | 0.30 | 1.52 | 0.98 | 0.34 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.04 | 0.02 | 0.00 | 0.07 | 0.03 | 0.06 | 0.02 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
104.56 | 0.11 | 1.10 | 0.42 | 0.72 | 1.79 | 46.55 | 0.41 | 0.41 | 3.73 |
Cash ROIC |
208.67% | 141.69% | (154.34%) | 71.48% | (66.91%) | (44.00%) | (12.78%) | (25.50%) | (43.70%) | (19.18%) |
Accounts Receivable Turnover |
— | — | — | 18.35 | 62.09 | 47.09 | 4.53 | 10.79 | 10.86 | 9.91 |
Accounts Payable Turnover |
0.78 | 0.28 | 0.73 | 0.10 | 0.32 | 2.23 | 1.86 | 5.85 | 5.96 | 4.29 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.56 | 1.30 | 1.82 | 1.56 | 3.49 | 2.85 | 1.94 |
Average Days of Payables |
168.97 | 1,067.35 | 855.61 | 3,186.35 | 889.86 | 132.92 | 386.19 | 59.90 | 83.59 | 85.96 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 522.84 | 336.71 | 327.51 | 453.31 | 132.87 | 170.07 | 204.46 |
Average Receivables |
— | — | — | 0.00 | 0.00 | 0.00 | 0.96 | 2.23 | 3.21 | 3.66 |
Average Payables |
0.08 | 0.02 | 0.07 | 0.11 | 0.08 | 0.05 | 1.42 | 2.69 | 4.06 | 5.60 |
Average Inventory |
— | — | — | 0.02 | 0.02 | 0.06 | 1.70 | 4.51 | 8.51 | 12.38 |
Average Assets |
0.37 | 0.16 | 0.70 | 0.62 | 0.57 | 1.62 | 15.72 | 28.30 | 28.95 | 30.32 |
Average Common Equity |
(0.45) | (0.44) | (0.36) | (0.45) | (0.92) | (0.47) | 10.87 | 21.42 | 22.35 | 23.26 |
Columns are period end dates